Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 593,947 | $269,271,812 | +56% | 0.16% |
| 2. | Renaissance Technologies Jim Simons | 505,048 | $228,968,561 | -32% | 0.36% |
| 3. | Citadel Investment Group Ken Griffin | 427,060 | $193,611,922 | +147% | 0.03% |
| 4. | Squarepoint Ops LLC Maxime Fortin (Cio) | 389,020 | $176,366,107 | -36% | 0.19% |
| 5. | GLG Partners Noam Gottesman | 380,735 | $172,610,019 | +5% | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $389.95 | 5,710 | $2,226,614.50 | 115,968 | 2025-08-06 | Filing | |
| $389.08 | 4,290 | $1,669,153.20 | 110,258 | 2025-08-06 | Filing | |
| $389.84 | 3,366 | $1,312,201.44 | 45,000 | 2025-08-06 | Filing | |
| $389.36 | 1,634 | $636,214.24 | 41,634 | 2025-08-06 | Filing | |
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $471.43 | 4,237 | $1,997,448.91 | 58,934 | 2026-02-19 | Filing | |
| $470.54 | 11,712 | $5,510,964.48 | 63,171 | 2026-02-19 | Filing | |
| $469.61 | 7,241 | $3,400,446.01 | 74,883 | 2026-02-19 | Filing | |
| $468.57 | 19,662 | $9,213,023.34 | 82,124 | 2026-02-19 | Filing | |
| $467.75 | 10,263 | $4,800,518.25 | 101,786 | 2026-02-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,510,182 | $11,565,309,006 | 1.57% | |
| 2. | 24,105,823 | $10,928,615,915 | 0.16% | |
| 3. | 23,751,989 | $10,768,201,653 | 0.18% | |
| 4. | 17,316,344 | $7,850,543,946 | 1.45% | |
| 5. | 11,689,539 | $5,299,569,401 | 0.18% |
News See All
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026Vertex Pharmaceuticals Incorporated misses on earnings expectations.
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy.
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Here’s Why Hardman Johnston Global Equity Strategy Sold Vertex Pharmaceuticals (VRTX)
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the fourth quarter of 2025. A copy of the letter can...
Bernstein Names Vertex (VRTX) a "Top Biotech Pick" for 2026 Following Upgrade to Outperform
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best future stocks to buy for the long term.
12 Best Future Stocks to Buy For the Long Term
On January 6, Dan Ives of Wedbush Securities joined 'Closing Bell' on CNBC to suggest that the tech bull market continues to play out.
Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook?
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can ...
Hedge Fund Resource Center